A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Baricitinib Impurity 40 - Request Quote

Picture of Baricitinib Impurity 40

Baricitinib Impurity 40

SZ CAT No:SZ-B038056
CAS No
NA
Mol.F.
C14H17N7O2S
Mol.Wt.
347.4
Inv. Status
Synthesis on demand

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Baricitinib Impurity 40 is chemically 2-(3-(4-(6-aminopyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile. Baricitinib Impurity 40 is supplied with detailed characterization data compliant with regulatory guideline. Baricitinib Impurity 40 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Baricitinib.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

buy high quality Baricitinib Impurity 40

Purchase Baricitinib Impurity 40

Baricitinib Impurity 40 suppliers

Baricitinib Impurity 40 manufacturers

Baricitinib Impurity 40 price

Order Baricitinib Impurity 40

Enquire Baricitinib Impurity 40

Baricitinib Impurity 40 cost

Baricitinib Impurity 40 Supplier

Baricitinib Impurity 40 Distributor

Baricitinib Impurity 40 for Method Validation

Baricitinib Reference Standard

Baricitinib Impurity 40 for ANDA Filing

Baricitinib Impurity 40 for Forced Degradation Studies

Baricitinib Impurity 40 Identification Standards

Baricitinib Impurity 40 for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,